Sasha Bogdanovich, University of Kentucky
Younghee Kim, University of KentuckyFollow
Takeshi Mizutani, University of KentuckyFollow
Reo Yasuma, University of KentuckyFollow
Laura Tudisco, Institute of Genetics and Biophysics—CNR, Italy
Valeria Cicatiello, Institute of Genetics and Biophysics—CNR, Italy
Ana Bastos-Carvalho, University of KentuckyFollow
Nagaraj Kerur, University of KentuckyFollow
Yoshio Hirano, University of KentuckyFollow
Judit Z. Baffi, University of KentuckyFollow
Valeria Tarallo, University of Kentucky
Shengjian Li, University of KentuckyFollow
Tetsuhiro Yasuma, University of KentuckyFollow
Parthasarathy Arpitha, University of Kentucky
Benjamin James Fowler, University of KentuckyFollow
Charles B. Wright, University of KentuckyFollow
Ivana Apicella, Institute of Genetics and Biophysics—CNR, Italy
Adelaide Greco, University of Naples, Italy
Arturo Brunetti, University of Naples, Italy
Menotti Ruvo, Istituto di Biostrutture e Bioimmagini, Italy
Annamaria Sandomenico, Istituto di Biostrutture e Bioimmagini, Italy
Miho Nozaki, Nagoya City University, Japan
Ryo Ijima, Nagoya University, Japan
Hiroki Kaneko, Nagoya University, Japan
Yuichiro Ogura, Nagoya City University, Japan
Hiroko Terasaki, Nagoya University, Japan
Balamurali K. Ambati, University of Utah
Jeanette H. W. Leusen, University Medical Center Utrecht, The Netherlands
Wallace Y. Langdon, University of Western Australia, Australia
Michael R. Clark, University of Cambridge, UK
Bradley D. Gelfand, University of KentuckyFollow
Jayakrishna Ambati, University of KentuckyFollow


Aberrant angiogenesis is implicated in diseases affecting nearly 10% of the world’s population. The most widely used anti-angiogenic drug is bevacizumab, a humanized IgG1 monoclonal antibody that targets human VEGFA. Although bevacizumab does not recognize mouse Vegfa, it inhibits angiogenesis in mice. Here we show bevacizumab suppressed angiogenesis in three mouse models not via Vegfa blockade but rather Fc-mediated signaling through FcγRI (CD64) and c-Cbl, impairing macrophage migration. Other approved humanized or human IgG1 antibodies without mouse targets (adalimumab, alemtuzumab, ofatumumab, omalizumab, palivizumab and tocilizumab), mouse IgG2a, and overexpression of human IgG1-Fc or mouse IgG2a-Fc, also inhibited angiogenesis in wild-type and FcγR humanized mice. This anti-angiogenic effect was abolished by Fcgr1 ablation or knockdown, Fc cleavage, IgG-Fc inhibition, disruption of Fc-FcγR interaction, or elimination of FcRγ-initated signaling. Furthermore, bevacizumab’s Fc region potentiated its anti-angiogenic activity in humanized VEGFA mice. Finally, mice deficient in FcγRI exhibited increased developmental and pathological angiogenesis. These findings reveal an unexpected anti-angiogenic function for FcγRI and a potentially concerning off-target effect of hIgG1 therapies.

Document Type


Publication Date


Notes/Citation Information

Published in Signal Transduction and Targeted Therapy, v. 1, article 15001, p. 1-14.

© 2016 West China Hospital, Sichuan University

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit

Due to the large number of authors, only the first 30 and the authors affiliated with the University of Kentucky are listed in the author section above. For the complete list of authors, please download this article.

Digital Object Identifier (DOI)

Funding Information

JA was supported by NIH grants DP1GM114862, R01EY018350, R01EY018836, R01EY020672, R01EY022238, R01EY024068, R21EY019778 and RC1EY020442, Doris Duke Distinguished Clinical Scientist Award, Burroughs Wellcome Fund Clinical Scientist Award in Translational Research, Ellison Medical Foundation Senior Scholar in Aging Award, Foundation Fighting Blindness Individual Investigator Research Award, Carl Marshall Reeves Foundation, Harrington Discovery Institute Scholar-Innovator Award, John Templeton Foundation, Dr E. Vernon Smith and Eloise C. Smith Macular Degeneration Endowed Chair, and Research to Prevent Blindness departmental unrestricted grant; SDF by Associazione Italiana Ricerca sul Cancro (AIRC) grant no. IG11420 and Italian Ministry for Scientific Research, projects PON01_02342 and PON01_01434; MR and AS by Italian Ministry for Scientific Research, grants FIRB MERIT N° RBNE08NKH7_003 and PON01_01602, PON01_02342. JZB by NIH K08EY021521 and University of Kentucky Physician Scientist Award; BJF and SB by NIH T32HL091812 and UL1RR033173; YH by Alcon Research Award; AB-C by the Program for Advanced Medical Education (sponsored by Fundação Calouste Gulbenkian, Fundação Champalimaud, Ministério da Saúde and Fundação para a Ciência e Tecnologia, Portugal) and Bayer Global Ophthalmology Research Award; YH by Alcon Japan Research award; NK by Beckman Initiative for Macular Research and NIH K99/R00EY024336; TY by Fight for Sight Postdoctoral Award; CBW by International Retinal Research Foundation; BDG by American Heart Association and International Retinal Research Foundation; BKA by NIH R01EY017182 and R01EY017950, VA Merit Award, and Department of Defense.

Related Content

Supplementary Information accompanies the paper on the Signal Transduction and Targeted Therapy website (

sigtrans20151-s1.pdf (1362 kB)
Supplementary Figures